HighTower Advisors’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
HighTower Advisors's CORT Position: Q3 2026 in Review
HighTower Advisors reduced its Corcept Therapeutics (CORT) stake by 3.2% in Q3 2026, selling an estimated $35K and leaving 9,781 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2190.
HighTower Advisors first reported a position in CORT in Q4 2017 and has held it in 14 quarters since. The position peaked at $11.5M in Q1 2025. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- HighTower Advisors held 9,781 shares of Corcept Therapeutics worth $1.13M as of Q3 2026.
- HighTower Advisors sold 325 Corcept Therapeutics shares in Q3 2026, an estimated $35K.
- Corcept Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #2190 holding.
- HighTower Advisors first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 14 quarters since.
- HighTower Advisors's Corcept Therapeutics position peaked at $11.5M in Q1 2025.
- 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.